Abstract: Provided are an IL-10 monomer fusion protein and use thereof, which relate to the field of biomedicine. The fusion protein includes an antibody and an IL-10 monomer. The fusion protein of the present disclosure has a relatively strong targeting property, so that the safety is remarkably improved. Moreover, the protein may effectively treat or prevent various tumors or inflammatory diseases.

Abstract: The present disclosure relates to the field of biomedicine, in particular to an anti-PD-L1 antibody and the use thereof. The anti-PD-L1 antibody or the antigen-binding fragment thereof provided in the present disclosure binds to a PD-L1 protein with a high affinity and high specificity, can effectively block the interaction between PD-L1 expressed on a cell surface and PD-1, and has the biological function activity of stimulating the production of cytokine, and has wide application prospects.

Abstract: The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of the PD-1 to PD-L1 and PD-L2. Therefore, the antibody or antigen-binding fragment thereof, and its related nucleic acid, vector, cell or pharmaceutical composition can be used to prepare a medicament for the treatment of PD-1-mediated diseases or conditions.

Abstract: Provided is an anti-TIGIT antibody or an antigen-binding fragment thereof. The antibody or the antigen-binding fragment thereof has a higher affinity for TIGIT, has functional characteristics in a plurality of aspects, and may be used alone or in combination with other reagents for treating cancers, and diseases related to immunity and inflammation.

Abstract: The present application relates to the field of biomedicines, in particular to an antibody targeting CD47 and an application thereof. The anti-CD47 antibody provided by the present application may specifically bind to tumor cells, block the signal of human SIRP? and human CD47, and promote the phagocytosis of the tumor cells by macrophages. The antibody has high affinity, strong specificity, and good safety. The red blood cell (RBC) agglutination is not caused, and it shows very weak binding to RBC and platelets.

Abstract: Provided are a human PD-1 antibody, an antigen-binding fragment thereof and a medical use thereof. A chimeric antibody containing a complementarity determining region (CDR) of the antibody, a pharmaceutical composition containing the human PD-1 antibody and the antigen-binding fragment thereof, and a use of the antibody in preparation of a drug for treating a disease or a disorder are further disclosed.